NeuroSense Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
NeuroSense Therapeutics Return on Equity (ROE) Growth & History (NRSN)
NeuroSense Therapeutics's return on equity was −2,174.98% for fiscal 2025.
View full NeuroSense Therapeutics company overviewNeuroSense Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2,174.98% | +705.14 pp |
| 2024 | 2024-12-31 | −2,880.11% | −2277.71 pp |
| 2023 | 2023-12-31 | −602.40% | −433.65 pp |
| 2022 | 2022-12-31 | −168.75% | −85.13 pp |
| 2021 | 2021-12-31 | −83.62% | +275.03 pp |
| 2020 | 2020-12-31 | −358.66% | — |
NeuroSense Therapeutics quarterly return on equity
Q4.24
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −409.32% | — |
NeuroSense Therapeutics return on equity trends
Over the last five fiscal years, NeuroSense Therapeutics's return on equity decreased from −358.66% to −2,174.98%, a change of −1816.32 percentage points. The latest reported quarter, Q4 2024, shows −409.32%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NeuroSense Therapeutics source filings ↗